Solène Vigoureux , Paul Maurice , Jeanne Sibiude , Charles Garabedian , Nicolas Sananès
{"title":"[妊娠头三个月预防 Rh D 同种免疫:法国妇产科医师学会临床实践指南]。","authors":"Solène Vigoureux , Paul Maurice , Jeanne Sibiude , Charles Garabedian , Nicolas Sananès","doi":"10.1016/j.gofs.2024.02.026","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To provide recommendations for the prevention of Rh D alloimmunization in the first trimester of pregnancy.</p></div><div><h3>Materials and methods</h3><p>The quality of evidence of the literature was assessed following the GRADE methodology with questions formulated in the PICO format (Patients, Intervention, Comparison, Outcome) and outcomes defined a priori and classified according to their importance. An extensive bibliographic search was performed on Pubmed, Cochrane, EMBASE, and Google Scholar databases. The quality of evidence was assessed (high, moderate, low, very low) and a recommendation was formulated: (i) strong, (ii) weak, or (iii) no recommendation. The recommendations were reviewed in two rounds with reviewers from the scientific board of the French College of the OB/GYN (Delphi survey) to select the consensus recommendations.</p></div><div><h3>Results</h3><p>The three recommendations from PICO questions reached agreement using the Delphi method. It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in case of abortion or miscarriage, in RhD negative patients when the genitor is RhD positive or unknown (Weak recommendation. Very low-quality evidence). It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in cases of bleeding in an ongoing intrauterine pregnancy (Weak recommendation. Very low-quality evidence). The literature data are insufficient in quality and quantity to determine if the injection of Rh D immunoglobulin reduces the risk of alloimmunization in the case of an ectopic pregnancy (No recommendation. Very low-quality evidence).</p></div><div><h3>Conclusion</h3><p>Even though the quality of evidence from the studies is very low, it is recommended not to administer Rh D immunoglobulin in case of abortion, miscarriage or bleeding before 12 weeks of amenorrhea. The quality of evidence was too low to issue a recommendation regarding ectopic pregnancy.</p></div>","PeriodicalId":56056,"journal":{"name":"Gynecologie Obstetrique Fertilite & Senologie","volume":"52 7","pages":"Pages 446-453"},"PeriodicalIF":0.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prévention de l’allo-immunisation anti-RH1 au premier trimestre de la grossesse : recommandations pour la pratique clinique du Collège national des gynécologues-obstétriciens français\",\"authors\":\"Solène Vigoureux , Paul Maurice , Jeanne Sibiude , Charles Garabedian , Nicolas Sananès\",\"doi\":\"10.1016/j.gofs.2024.02.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To provide recommendations for the prevention of Rh D alloimmunization in the first trimester of pregnancy.</p></div><div><h3>Materials and methods</h3><p>The quality of evidence of the literature was assessed following the GRADE methodology with questions formulated in the PICO format (Patients, Intervention, Comparison, Outcome) and outcomes defined a priori and classified according to their importance. An extensive bibliographic search was performed on Pubmed, Cochrane, EMBASE, and Google Scholar databases. The quality of evidence was assessed (high, moderate, low, very low) and a recommendation was formulated: (i) strong, (ii) weak, or (iii) no recommendation. The recommendations were reviewed in two rounds with reviewers from the scientific board of the French College of the OB/GYN (Delphi survey) to select the consensus recommendations.</p></div><div><h3>Results</h3><p>The three recommendations from PICO questions reached agreement using the Delphi method. It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in case of abortion or miscarriage, in RhD negative patients when the genitor is RhD positive or unknown (Weak recommendation. Very low-quality evidence). It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in cases of bleeding in an ongoing intrauterine pregnancy (Weak recommendation. Very low-quality evidence). The literature data are insufficient in quality and quantity to determine if the injection of Rh D immunoglobulin reduces the risk of alloimmunization in the case of an ectopic pregnancy (No recommendation. Very low-quality evidence).</p></div><div><h3>Conclusion</h3><p>Even though the quality of evidence from the studies is very low, it is recommended not to administer Rh D immunoglobulin in case of abortion, miscarriage or bleeding before 12 weeks of amenorrhea. The quality of evidence was too low to issue a recommendation regarding ectopic pregnancy.</p></div>\",\"PeriodicalId\":56056,\"journal\":{\"name\":\"Gynecologie Obstetrique Fertilite & Senologie\",\"volume\":\"52 7\",\"pages\":\"Pages 446-453\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologie Obstetrique Fertilite & Senologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468718924000813\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologie Obstetrique Fertilite & Senologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468718924000813","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
摘要为妊娠头三个月预防 Rh D 免疫提供建议:按照 GRADE 方法评估文献的证据质量,以 PICO 格式(患者、干预、比较、结果)提出问题,事先定义结果并根据其重要性进行分类。在 Pubmed、Cochrane、EMBASE 和 Google Scholar 数据库中进行了广泛的文献检索。对证据质量进行评估(高、中、低、极低),并提出建议:(i) 强、(ii) 弱或 (iii) 无建议。法国妇产科学院科学委员会的评审员对这些建议进行了两轮评审(德尔菲调查),以选出共识建议:结果:通过德尔菲法,来自 PICO 问题的三项建议达成了一致。建议在妊娠 12 周前不要给 RhD 阴性患者注射 Rh D 免疫球蛋白,以降低在流产或堕胎时发生同种异体免疫的风险,如果遗传因子为 RhD 阳性或未知(弱建议。证据质量极低)。建议在妊娠 12 周前不注射 Rh D 免疫球蛋白,以降低宫内妊娠出血时的同种免疫风险(弱推荐。证据质量极低)。文献数据在质量和数量上都不足以确定注射 Rh D 免疫球蛋白是否能降低宫外孕患者发生同种免疫的风险(无建议:尽管研究证据的质量很低,但建议在流产、流产或停经 12 周前出血的情况下不要注射 Rh D 免疫球蛋白。由于证据质量太低,无法就宫外孕提出建议。
Prévention de l’allo-immunisation anti-RH1 au premier trimestre de la grossesse : recommandations pour la pratique clinique du Collège national des gynécologues-obstétriciens français
Objective
To provide recommendations for the prevention of Rh D alloimmunization in the first trimester of pregnancy.
Materials and methods
The quality of evidence of the literature was assessed following the GRADE methodology with questions formulated in the PICO format (Patients, Intervention, Comparison, Outcome) and outcomes defined a priori and classified according to their importance. An extensive bibliographic search was performed on Pubmed, Cochrane, EMBASE, and Google Scholar databases. The quality of evidence was assessed (high, moderate, low, very low) and a recommendation was formulated: (i) strong, (ii) weak, or (iii) no recommendation. The recommendations were reviewed in two rounds with reviewers from the scientific board of the French College of the OB/GYN (Delphi survey) to select the consensus recommendations.
Results
The three recommendations from PICO questions reached agreement using the Delphi method. It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in case of abortion or miscarriage, in RhD negative patients when the genitor is RhD positive or unknown (Weak recommendation. Very low-quality evidence). It is recommended not to administer Rh D immunoglobulin before 12 weeks of gestation to reduce the risk of alloimmunization in cases of bleeding in an ongoing intrauterine pregnancy (Weak recommendation. Very low-quality evidence). The literature data are insufficient in quality and quantity to determine if the injection of Rh D immunoglobulin reduces the risk of alloimmunization in the case of an ectopic pregnancy (No recommendation. Very low-quality evidence).
Conclusion
Even though the quality of evidence from the studies is very low, it is recommended not to administer Rh D immunoglobulin in case of abortion, miscarriage or bleeding before 12 weeks of amenorrhea. The quality of evidence was too low to issue a recommendation regarding ectopic pregnancy.
期刊介绍:
Gynécologie Obstétrique Fertilité & Sénologie est un mensuel scientifique d''information et de formation destiné aux gynécologues, aux obstétriciens, aux sénologues et aux biologistes de la reproduction. La revue, dans ses éditoriaux, articles originaux, mises au point, lettres à la rédaction et autres rubriques, donne une information actualisée ayant trait à l''obstétrique et à la gynécologie et aux différentes spécialités développées à partir de ces deux pôles : médecine de la reproduction, médecine maternelle et fœtale, périnatalité, endocrinologie, chirurgie gynécologique, cancérologie pelvienne, sénologie, sexualité, psychosomatique…